US2006121117A1PendingUtilityA1

Anti-angiogenic compositions and methods of use

Assignee: ANGIOTECH PHARM INCPriority: Jul 19, 1993Filed: Jan 17, 2006Published: Jun 8, 2006

Est. expiryJul 19, 2013(expired)· nominal 20-yr term from priority

Inventors:William L. Hunter Lindsay Machan A. Arsenault Helen Burt John Jackson Stephen Dordunoo

A61P 7/04A61P 35/00A61P 43/00A61P 9/00A61P 7/02A61P 9/14A61P 9/10A61P 27/02A61P 13/02A61P 11/00A61P 19/02A61P 1/16A61P 1/04A61K 9/14A61K 33/30A61L 2300/606A61K 45/06A61K 33/06A61K 31/555A61K 38/57A61K 31/565C07C 233/64A61K 9/1635A61K 31/4745A61K 33/00C08L 2203/02A61K 9/7007A61L 2300/416A61K 9/5146A61L 2430/36A61K 31/426A61K 31/702A61K 31/122Y10S977/773A61K 31/427A61K 31/203A61K 31/165A61K 9/1647A61L 31/10Y10S977/915A61K 31/335B82Y 5/00A61K 9/1658A61K 9/1641C08L 2312/00A61K 31/337C07K 14/811A61L 31/16A61K 9/0051A61K 9/5031A61K 9/0048A61K 9/5153A61K 31/519A61K 31/525A61K 31/57C08L 29/04C08L 67/04A61L 31/145A61K 31/136A61K 9/0019C08L 23/0853A61L 2300/622A61K 31/185A61K 31/20A61K 33/24

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims

exact text as granted — not AI-modified

1 . A composition, comprising: 
 (a) a compound which disrupts microtubule function; and    (b) a polymeric carrier which comprises a copolymer of lactic acid and glycolic acid.    
     
     
         2 . The composition according to  claim 1  wherein said composition is formed into microspheres having an average size of between 0.5 and 200 μm.  
     
     
         3 . The composition according to  claim 1  wherein said composition is formed into a film with a thickness of between 100 μm and 2 mm.  
     
     
         4 - 7 . (canceled)  
     
     
         8 . The composition according to  claim 1  wherein said compound which disrupts microtubule function is paclitaxel.  
     
     
         9 . The composition according to  claim 1  wherein said compound which disrupts microtubule function is selected from the group consisiting of estramustine, colchicine, methotrexate, curacin-A, epothilone, vinblastine and tBCEU.

Join the waitlist — get patent alerts

Track US2006121117A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.